CELLTRION
Celltrion (KRX:068270) announced today that it has signed an agreement to acquire product assets for the Asia Pacific region from Takeda Pharmaceuticals International AG (“Takeda”) in an effort to strengthen its R&D capabilities in the Global Small Molecule Drug sector.
This signing allows Celltrion to acquire Takeda’s Primary Care businesses in the Asia Pacific region and secure rights for patent, trademark, approval and sales of a total of 18 prescription and over-the-counter brands currently available in 9 markets in the region, namely, South Korea, Thailand, Taiwan, Hong Kong, Macau, the Philippines, Singapore, Malaysia and Australia. These products grossed a combined sale of approximately $140 million USD (approx. KRW 170 billion) in Fiscal Year 2018 in these markets. These products are expected to be distributed by Celltrion Pharm, a Celltrion affiliate company, in Korea and by Celltrion Healthcare in other AP territories leveraging their distribution and marketing capabilities.
Celltrion agreed to acquire these rights for USD 278.3 million. It will acquire the business through its wholly owned subsidiary in Singapore. Subject to approval from relevant local and/or foreign authorities, Celltrion plans to complete the transaction by the end of the fourth quarter this year.
The acquired product portfolio includes global new drug Nesina, Actos (both for diabetes) and Edarbi (hypertension) and also well-known OTC drugs such as Whituben (cold remedy) and Albothyl (stomatitis). Among them, Nesina and Edarbi are protected through product patents until 2026 and 2027, respectively.
Takeda and Celltrion have also entered into a manufacturing and supply agreement under which Takeda will continue to manufacture the portfolio of divested products and supply them to Celltrion. Celltrion plans to receive relevant technology transfer to start local manufacturing at Celltrion Pharma’s cGMP production facilities for some of the key acquired products for sales in local and foreign markets.
Celltrion’s first large-scale M&A deal, this acquisition gives Celltrion a pivotal opportunity to establish a robust presence as a local original drug provider in the Korean market. Demand has been high for treatments for chronic diseases such as diabetes, hypertension and hyperlipidemia in Korea. Despite this trend, multinational pharmaceuticals have constituted a majority of the local supplies. Celltrion hopes to position itself as a stable supplier of high-quality, made-in-Korea original drugs and contribute to the reinforced financial strength of the national health system.
The deal also provides significant potential for the company’s sustainable growth. Celltrion plans to quickly land these products in the Asia Pacific market, tapping into Takeda’s established brand power for prescription drugs.
Celltrion expects this acquisition to allow the company to mature as a comprehensive global pharmaceutical company, as it adds a powerful small molecule product lineup to its already strong biopharmaceutical pipeline, which includes autoimmune disease and anti-cancer drugs.
The competitive over-the-counter drug brands added through this deal will also help raise Celltrion’s brand awareness among consumers.
Meanwhile, diabetes and hypertension drug markets in the Asia Pacific region were worth KRW 3 trillion and KRW 2.76 trillion1 last year, respectively. The combined market size of these two segments is expected to double to KRW 11 trillion by 2030.
This deal is expected to strengthen Celltrion’s global R&D capability and help spur the development of new drugs and insulin biosimilars. Celltrion will utilize the new drug pipeline to complete its portfolio for diabetes and hypertension treatments. Based on these efforts, Celltrion will continue to tap the U.S. and global procurement markets to provide high-quality and cost-effective pharmaceuticals around the world.
Celltrion CEO Kee Woo Sung said, ”With 17 million diabetes and hypertension patients in Korea alone and more than 60% of the elderly population have three or more chronic diseases, the market for chronic disease drugs is becoming more important. By acquiring the rights for a selection of Takeda’s products in Asia Pacific, Celltrion will be able to localize essential drugs for diabetes and hypertension, for which many local patients had to depend on imported drugs. This transaction will help us contribute to improved public healthcare and more resilient National Health finance in this super-aged society. Celltrion will take a big step to become a comprehensive global biopharmaceutical company.”
About Celltrion, Inc
Headquartered in Incheon, Korea, Celltrion is a leading biopharmaceutical company, specializing in the research, development and manufacture of small molecules, biosimilars and innovative drugs. Celltrion strives to provide more affordable biosimilar mAbs to patients who previously had limited access to advanced therapeutics. Celltrion received FDA and EC’s approval for INFLECTRA® and Remsima® , respectively, the world’s first mAb biosimilar approved from regulatory agencies in developed countries. For more information, visit www.celltrion.com .
1. IQVIA, 2019, Market size of diabetes treatments in 8 APAC countries and hypertension treatments in 6 APAC countries
View source version on businesswire.com: https://www.businesswire.com/news/home/20200611005429/en/
Link:
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Suzano Forms Partnership with Tencent and Ecofuturo Institute at COP30 for AI-Powered Conservation and Nature Education20.11.2025 18:25:00 CET | Press release
New agreement signed at COP30 will see organisations collaborating to use artificial intelligence tools for biodiversity monitoring and digital platforms to boost public engagement in conservation efforts. The world’s largest pulp supplier, Suzano, today announces the signing of a Memorandum of Understanding (MoU) with the multinational technology business Tencent and the Brazilian non-profit Ecofuturo Institute, to pioneer new digital approaches to drive public engagement in conservation. The collaboration will leverage Suzano’s expertise in sustainable forestry, Tencent’s cutting-edge digital technology, and Ecofuturo’s expertise in environmental education, to pilot joint initiatives in both Brazil and China. These include enhancing ecological awareness, accelerating biodiversity solutions, and leveraging digital platforms to foster public engagement in conservation. The partnership will result in a pilot project where advanced AI tools for species recognition developed by Tencent’s
EMVCo Working on How Global Specifications Can Support Agentic Payments20.11.2025 17:38:00 CET | Press release
EMVCo – the technical body that creates and manages EMV® Specifications and programmes that enable seamless and secure card-based payments worldwide – has announced that it is working on how global specifications can support innovation in agentic payment solutions by increasing trust and interoperability across the ecosystem. Agentic commerce is rapidly reshaping the shopping experience by enabling AI agents to act on the consumer’s behalf. This is driving significant momentum for agentic payments, which introduce AI agents as new actors that can initiate transactions with merchants – without requiring direct involvement from the consumer. While agentic payments have the potential to increase convenience and personalisation, they present unique considerations for how transactions are initiated, authenticated and secured. As industry adoption and innovation accelerate, a globally interoperable and scalable approach may be beneficial in realising trusted agentic payments for consumers, m
Université Paris-Saclay and Owkin: A Unique Alliance to Propel University Medical Research to the Top of the European Rankings Through AI20.11.2025 15:17:00 CET | Press release
Université Paris-Saclay and Owkin announce the signing of a memorandum of understanding to explore the potential of K Pro Free - Owkin’s AI co-pilot for biology - for use by Paris-Saclay. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20251120130113/en/ K Pro Free will now be available to the entire Université Paris-Saclay community, and in particular teachers, researchers and doctoral students working in the biomedical sciences. The partnership includes workshops, training sessions and events designed to promote the discovery and adoption of K Pro Free, as well as the co-organization of communication and dissemination initiatives around the use of AI in health. In this way, the partnership will promote user training, but also enrich and continuously improve the co-pilot's models through feedback and use cases from the l’Université Paris-Saclay community. This partnership is part of Université Paris-Saclay’s strategy to integr
Frasca Advances Flight Training Technology with New Visual System Powered by Unreal Engine20.11.2025 15:05:00 CET | Press release
Frasca International, Inc., a FlightSafety International company and leader in flight simulation, today announced the launch of VITAL FVS 100, the next evolution of its visual system technology. Building on the proven TruVision Global platform, VITAL FVS 100 was developed using Epic Games’ Unreal Engine and delivers unprecedented realism, scalability, and innovation in pilot training. The Unreal-powered VITAL FVS 100 system introduces major advancements in visual fidelity and training realism, further enhancing the capabilities of Frasca, a leading developer of flight simulators and training devices. The new system includes physically based renderings, advanced lighting effects, and a new volumetric cloud model that creates dynamic, weather-rich environments. Terrain imagery now includes one-meter resolution coverage for the contiguous United States and Hawaii, with expanded global datasets covering European buildings and tree covered regions. Additionally, enhanced particle effects re
GigaOm Radar for Vector Databases v3 Positions Vespa.ai as a Leader and Outperformer20.11.2025 15:00:00 CET | Press release
Vespa Recognized for Integrated Ranking, Multimodal Search, and Production-Scale AI Performance Vespa.ai, the creator of the AI Search Platform for building and deploying large-scale, real-time AI applications powered by big data, today announced its recognition as a Leader and Outperformer in the GigaOm Radar for Vector Databases v3, marking the company’s third consecutive year being evaluated in GigaOm’s vector database research. Now in its third edition, the report compares 17 leading open source and commercial solutions using GigaOm’s structured evaluation framework. In addition to core table-stakes capabilities, the Radar reviews each vendor’s key features, emerging strengths, and broader business criteria. The shift from Sonar to Radar reflects the technology’s transition into mainstream adoption. GigaOm names Vespa.ai a leader for its ability to manage complex data, optimize results at scale, and support multimodal AI workloads. The report highlights Vespa’s native tensor suppor
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom